Echo Global Logistics public and InnerWorkings are the two ventures that brought Eric Lefkofsky into the limelight. But then Groupon is the most recognized of all his companies. Eric earned up to $1.79 billion with e-commerce startups over the years, and all indications point out that he is destined to accomplish greater things. He has recently launched Tempus, which is his latest company with very lofty goals. He has dedicated this company to assemble an extensive genomic database for cancer.
There are also a number of nonprofit firms that researching on the best disease treatment methods. The reason behind the successful development of this industry storing databases and performing genetic screening tests are not as expensive as they were before. This area has advanced considerably, but for Erick, Tempus has a competitive edge over these other firms and is destined to get bigger and more prosperous.In 2015, Erick saw it better to resign as Groupon’s CEO to have more time for himself so that he could direct his efforts towards building Tempus into a company like no other. He, however, remains the chairman of Groupon as well as the largest shareholder here. His first step towards developing Tempus into the company that he desired was to hire Kevin White, a geneticist with wide experience in the genetic industry.
About Eric Lefkofsky
Eric Lefkofsky is the CEO and the co-founder of Tempus, a company that battles cancer. He also co-founded various other companies including Lightbank, Groupon, Uptake Technologies, Mediaocean, Echo Global Logistics and InnerWorkings. Eric together with his wife Liz established a private charity organization called Lefkofsky Family Foundation that supports high-impact initiatives in the communities they serve.He is a trustee at various institutions including Lurie Children’s Hospital of Chicago, World Business Chicago and The Art Institute of Chicago. At the Steppenwolf Theatre Company in Chicago, Eric is the Board of Trustees chairperson. He is an author of the famous publication Accelerated Disruption as well as a University of Chicago professor. Eric graduated from the University of Michigan and earned a Juris Doctor from its Law School.
With more than twenty years of experience in cancer research and treatment, Dr Clay Siegall passion and commitment to cure cancer continues to fuel even more. He is the current co-founder chief executive officer of Seattle Genetics. Seattle Genetics is a biotechnology company whose main purpose if in finding therapies that aid in cancer treatment. As the chief executive officer Mr Siegall has spearheaded the company into production of ADC therapies that have received the approval of FDA. He has also led the company in the establishment and launch of ADCETRIS, an antibody drug conjugate that is being sold and used in more than sixty countries around the world.
His passion for medicine and especially oncology began after graduating from the University of Maryland with a bachelor’s degree in Zoology and later joined the George Washington University with a Ph.D IN Genetics. From there he worked at The National Cancer Institute as a staff and biotechnology fellow. He worked as a senior research investigator at Bristol-Myers Squibb Pharmaceutical Research Institute.
At Seattle Genetics, he works alongside his team to achieve their purpose in the treatment of cancer. He also led the company into several multi-million dollar deals for their ADC technology. He has also helped the company in achieving more than 1.2 billion of funds through inviting the public and private sectors to finance. He also pushes his team towards generating and coming up with more therapies that may help their patients across the world.
Through his career, he has always shown his determination in getting the cure and treatment of cancer. His empathy towards cancer drives him each day to work towards the cure. His efforts have been noticed through the publications he has written that help people understand cancer and how to make their loves more comfortable. He was also named the entrepreneur of the year by Ernst & Young.
Recently, Forbes wrote an article revealing that the company’s drugs were tested and found that they had created an impact on their patients. The patients who were given the brentuximab vedotin Adcetris were doing better than those who hadn’t. Which makes the drug quite valuable to the patients
One of the fields that has been growing and expanding greatly over the past couple of decades is medical science and biotechnology. Despite the many advances that have been made, we are still yet to completely eliminate diseases such as cancer, which are a major menace to our generation. This is the one fight that the CEO of the Biotech Company Seattle Genetics, Clay Siegall had in mind when he founded the clinic.
Less than two decades since Siegall started the clinical stage company, he is already presenting tremendous results to the population. The first of the treatments his labs developed has already gotten approval from the FDA and is now being sold as a therapy for patients that suffer from different types of cancer. The drug, Adcetris has become a brand globally and has been approved for use in more than 60 countries. In the first year of its sale, the drug generated sales of close to $350 million. Companies such as Takeda Pharmaceuticals have been helping the company sell the drug in Canada.
The interesting thing about Siegall and his company is the despite the fact that he is now publicly trading on NASDAQ, he has not stopped looking for ways to deal with different types of lymphomas. There are 12 more drugs that are in the clinical testing stage in his clinic, and they are all projected to be successful in dealing with different cancer types. The company also plans to expand their workforce by hiring one hundred more members of staff.
The company has been in the public limelight for all the right reasons. For instance, they recently got a visit from none other than the vice president Joe Bidden himself. Since the release of their drugs and the announcement that there is another of their drugs that is doing well in clinical runs, their shares have been doing well on NASDAQ.
The CEO founded the company in 1998 after working in various other biotechnology companies. He has vast experience in dealing with clinical research and the success that comes from this level of commitment to solving the problems of humanity is getting rewarded.
Learn more about Clay Siegall: